Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Wednesday Trading

<< Previous

Bullboard Posts

Next >>

Comment by Whalewatcher1on Dec 27, 2021 12:45pm

81 Views

Post# 34263900

RE:RE:RE:RE:RE:RE:RE:Wednesday Trading

How does this stock get uplisted to Nasdaq? They will need major $ raise to meet minimum listing requiremts. Search for yourself the Nasdaq listing requirements including year plus cash based on market guidance on developments, capital, share price, director independence etc. these guys had $2.4M cash in August, spending $2M a quarter and $6M market cap. Do you really think nasdaq will accept them? Massive dilution would be required at higher share price, and looks like another share consolidation. how does that happen?

<< Previous

Bullboard Posts

Next >>

Thesis Gold makes high-grade discovery at Ring Zone